指南与共识肾癌与肾肿瘤

肾肿块与局限性肾癌:AUA指南

Renal Mass and Localized Renal Cancer: AUA Guideline.
指南 / 共识 · J Urol · 2017-05-04

AUA指南聚焦成人临床局限性疑似恶性肾肿块(含实性强化肿瘤及Bosniak 3/4复杂囊性病变)的评估、咨询与管理。基于系统评价,按证据等级A/B/C给出强/中等/条件推荐,并含临床原则与专家意见。推荐对临床T1a病变优先部分肾切除、选择性使用热消融(尤其≤3.0 cm肿瘤),并更严格限定根治性肾切除的适用条件,强调个体化咨询与共同决策。

要点

  • 推荐对临床T1a病变优先选择部分肾切除,并选择性使用热消融,尤其适用于≤3.0 cm的肿瘤。
  • 推荐在明确选择标准下更严格地限定根治性肾切除的适用。
  • 强调根据患者整体健康/合并症、肿瘤学潜能、功能问题及不同管理策略的相对疗效与潜在并发症进行个体化咨询与共同决策。

核心结论

  • 临床局限性肾肿块患者的咨询与管理应考虑整体健康/合并症、肿块的肿瘤学潜能、相关功能问题以及各种管理策略的相对疗效/潜在并发症。

研究设计与样本

  • AUA指南基于美国医疗保健研究与质量局(Agency for Healthcare Research and Quality)的系统评价,并由作者及顾问方法学家补充。
  • 证据陈述基于证据体强度A/B/C级,分别对应强推荐/中等推荐/条件推荐,另有陈述以临床原则或专家意见呈现。

主要发现

  • 自2009年既往局限性肾肿块管理指南发布以来已取得很大进展,当前指南提供了关于评估/咨询及肾肿块活检演变作用的更新循证推荐。
  • 鉴于临床、肿瘤学及功能特征差异很大,未采用索引患者,专家组主张个体化咨询/管理。
  • 管理选项包括部分肾切除/根治性肾切除/热消融/主动监测,并回顾了比较有效性及潜在并发症的最新数据。
  • 肿瘤学问题被优先考虑,同时认识到功能结局对大多数局限性肾癌患者的生存质量非常重要。

关键数值与推荐

  • 推荐对临床T1a病变优先选择部分肾切除,并选择性使用热消融,尤其适用于≤3.0 cm的肿瘤。
  • 推荐在明确的选择标准下更严格地限定根治性肾切除的适用。
  • 明确界定了关于主动监测共同决策的重要考虑因素。
  • 证据陈述基于证据体强度A/B/C级,分别对应强推荐/中等推荐/条件推荐。

临床怎么用

  • 临床局限性肾肿块的管理选项包括部分肾切除、根治性肾切除、热消融和主动监测。
  • 对临床T1a病变优先选择部分肾切除,并选择性使用热消融,尤其适用于≤3.0 cm的肿瘤。
  • 根治性肾切除应在明确选择标准下更严格地限定使用。
  • 应就主动监测进行共同决策,并明确界定重要考虑因素。
  • 应根据患者整体健康/合并症、肿瘤学潜能、功能问题及不同策略的相对疗效/潜在并发症进行个体化咨询与管理。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This AUA Guideline focuses on evaluation/counseling and management of adult patients with clinically localized renal masses suspicious for cancer, including solid-enhancing tumors and Bosniak 3/4 complex-cystic lesions. MATERIALS AND METHODS: Systematic review utilized research from the Agency for Healthcare Research and Quality and additional supplementation by the authors and consultant methodologists. Evidence-based statements were based on body of evidence strength Grade A/B/C (Strong/Moderate/Conditional Recommendations, respectively) with additional statements presented as Clinical Principles or Expert Opinions. RESULTS: Great progress has been made since the previous guidelines on management of localized renal masses were released (2009). The current guidelines provide updated, evidence-based recommendations regarding evaluation/counseling of patients with clinically localized renal masses, including the evolving role of renal mass biopsy. Given great variability of clinical, oncologic and functional characteristics, index patients are not utilized and the panel advocates individualized counseling/management. Management options (partial nephrectomy/radical nephrectomy/thermal ablation/active surveillance) are reviewed including recent data about comparative effectiveness and potential morbidities. Oncologic issues are prioritized while recognizing that functional outcomes are of great importance for survivorship for most patients with localized kidney cancer. A more restricted role for radical nephrectomy is recommended following well-defined selection criteria. Priority for partial nephrectomy is recommended for clinical T1a lesions, along with selective use of thermal ablation, particularly for tumors ≤3.0 cm. Important considerations for shared decision-making about active surveillance are explicitly defined. CONCLUSIONS: Several factors should be considered during counseling/management of patients with clinically localized renal masses, including general health/comorbidities, oncologic potential of the mass, pertinent functional issues and relative efficacy/potential morbidities of various management strategies.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Campbell S, Uzzo RG, Allaf ME, et al. Renal Mass and Localized Renal Cancer: AUA Guideline. J Urol. 2017. PMID: 28479239. doi:10.1016/j.juro.2017.04.100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。